205 related articles for article (PubMed ID: 17235051)
1. Hand-foot and stump syndrome to sorafenib.
Lai SE; Kuzel T; Lacouture ME
J Clin Oncol; 2007 Jan; 25(3):341-3. PubMed ID: 17235051
[No Abstract] [Full Text] [Related]
2. Non-pigmenting fixed drug eruption induced by sorafenib.
Tanabe K; Amoh Y; Mii S; Eto H; Iwamura M; Katsuoka K
Acta Derm Venereol; 2010 May; 90(3):307. PubMed ID: 20526556
[No Abstract] [Full Text] [Related]
3. Sorafenib-induced palmoplantar hyperkeratosis.
Lountzis NI; Maroon MS
J Drugs Dermatol; 2008 Jun; 7(6):588-9. PubMed ID: 18561593
[TBL] [Abstract][Full Text] [Related]
4. Chloracne-like drug eruption associated with sorafenib.
Pickert A; Hughes M; Wells M
J Drugs Dermatol; 2011 Nov; 10(11):1331-4. PubMed ID: 22052319
[TBL] [Abstract][Full Text] [Related]
5. Erythema multiforme induced by sorafenib.
Feltes RA; Feito Rodríguez M; González-Beato MJ
Clin Exp Dermatol; 2009 Oct; 34(7):e368-9. PubMed ID: 19489856
[No Abstract] [Full Text] [Related]
6. Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor.
Autier J; Escudier B; Wechsler J; Spatz A; Robert C
Arch Dermatol; 2008 Jul; 144(7):886-92. PubMed ID: 18645140
[TBL] [Abstract][Full Text] [Related]
7. [Application monitoring of the use of sorafenib in papillary renal cell carcinoma].
Schrader AJ; Hegele A; Olbert P; Buer J; Jeron A; Hofmann R
Urologe A; 2007 Sep; 46(9):1291. PubMed ID: 17668165
[No Abstract] [Full Text] [Related]
8. Sorafenib: a promising new targeted therapy for renal cell carcinoma.
Wood LS; Manchen B
Clin J Oncol Nurs; 2007 Oct; 11(5):649-56. PubMed ID: 17962173
[TBL] [Abstract][Full Text] [Related]
9. Transient perforating folliculitis induced by sorafenib.
Minami-Hori M; Ishida-Yamamoto A; Komatsu S; Iiduka H
J Dermatol; 2010 Sep; 37(9):833-4. PubMed ID: 20883372
[No Abstract] [Full Text] [Related]
10. Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy.
Yang CH; Lin WC; Chuang CK; Chang YC; Pang ST; Lin YC; Kuo TT; Hsieh JJ; Chang JW
Br J Dermatol; 2008 Mar; 158(3):592-6. PubMed ID: 18070211
[TBL] [Abstract][Full Text] [Related]
11. Sorafenib: atypical cutaneous side effects.
Richetta AG; Maiani E; Carboni V; Carlomagno V; Cimillo M; Mattozzi C; Calvieri S
Eur J Dermatol; 2007; 17(6):549-50. PubMed ID: 17951148
[No Abstract] [Full Text] [Related]
12. [Clinical observation of 21 cases of metastatic renal cell carcinoma treated with sorafenib].
Xie XD; Piao Y; Liu ZZ
Zhonghua Zhong Liu Za Zhi; 2009 Sep; 31(9):714-5. PubMed ID: 20021872
[No Abstract] [Full Text] [Related]
13. Sorafenib and surgical complications: a case report of adverse reaction to sorafenib during treatment for renal cell carcinoma.
Eng FC; Easson AM; Szentgyorgyi E; Knox JJ
Eur J Surg Oncol; 2009 Feb; 35(2):219-21. PubMed ID: 17976949
[No Abstract] [Full Text] [Related]
14. Impact of sorafenib on health-related quality of life in Japanese patients with metastatic renal cell carcinoma: a prospective evaluation.
Miyake H; Kurahashi T; Yamanaka K; Kondo Y; Takenaka A; Inoue TA; Fujisawa M
BJU Int; 2010 Dec; 106(11):1643-7. PubMed ID: 20553261
[TBL] [Abstract][Full Text] [Related]
15. Sorafenib-induced erythema multiforme in metastatic renal cell carcinoma.
Bilaç C; Müezzinoğlu T; Ermertcan AT; Kayhan TC; Temeltaş G; Oztürkcan S; Temiz P
Cutan Ocul Toxicol; 2009; 28(2):90-2. PubMed ID: 19514932
[TBL] [Abstract][Full Text] [Related]
16. Severe sorafenib-induced hand-foot skin reaction.
Cuesta L; Betlloch I; Toledo F; Latorre N; Monteagudo A
Dermatol Online J; 2011 May; 17(5):14. PubMed ID: 21635836
[TBL] [Abstract][Full Text] [Related]
17. Localized palmar-plantar epidermal hyperplasia: a previously undefined dermatologic toxicity to sorafenib.
Beldner M; Jacobson M; Burges GE; Dewaay D; Maize JC; Chaudhary UB
Oncologist; 2007 Oct; 12(10):1178-82. PubMed ID: 17962611
[TBL] [Abstract][Full Text] [Related]
18. Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma.
Akaza H; Tsukamoto T; Murai M; Nakajima K; Naito S
Jpn J Clin Oncol; 2007 Oct; 37(10):755-62. PubMed ID: 17951335
[TBL] [Abstract][Full Text] [Related]
19. Leukocytoclastic vasculitis masquerading as hand-foot syndrome in a patient treated with sorafenib.
Chung NM; Gutierrez M; Turner ML
Arch Dermatol; 2006 Nov; 142(11):1510-1. PubMed ID: 17116852
[No Abstract] [Full Text] [Related]
20. Safety and efficacy of sorafenib in elderly patients treated in the North American advanced renal cell carcinoma sorafenib expanded access program.
Bukowski RM; Stadler WM; McDermott DF; Dutcher JP; Knox JJ; Miller WH; Hainsworth JD; Henderson CA; Hajdenberg J; Kindwall-Keller TL; Ernstoff MS; Drabkin HA; Curti BD; Chu L; Ryan CW; Hotte SJ; Xia C; Cupit L; Figlin RA
Oncology; 2010; 78(5-6):340-7. PubMed ID: 20733337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]